Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × avelumab × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 4 Carcinoma, Transitional Cell 4 Urethral Neoplasms 2 Ureteral Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Renal Cell 2 Carcinoma, Merkel Cell 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Osteosarcoma 1 Metastatic Urothelial Cancer 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Melanoma 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 10 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Letrozole 28 Fulvestrant 27 Paclitaxel 25 Trastuzumab 21 pembrolizumab 20 Capecitabine 19 ribociclib 18 trastuzumab deruxtecan 14 Specimen Handling 13 Anastrozole 13 palbociclib 12 abemaciclib 12 Cyclophosphamide 12 Carboplatin 12 exemestane 11 Tamoxifen 11 Blood Specimen Collection 11 pertuzumab 10 Magnetic Resonance Spectroscopy 10 130-nm albumin-bound paclitaxel 10 inavolisib 9 Radiotherapy 9 giredestrant 7 Surveys and Questionnaires 7 tucatinib 6 olaparib 6 Docetaxel 6 Biopsy 6 sacituzumab govitecan 5 eribulin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03573648 2026-03-19

ImmunoADAPT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡